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Staphylococcus aureus is a bacterial pathogen responsible for the majority of skin and soft tissue infections. Antibiotics are los-
ing their efficacy as treatment for skin and soft tissue infections as a result of increased resistance in a variety of pathogens, in-
cluding S. aureus. It is thus imperative to explore alternative antimicrobial treatments to ensure future treatment options for
skin and soft tissue infections. A select few lantibiotics, a group of natural defense peptides produced by bacteria, inhibit the
growth of numerous clinical S. aureus isolates, including methicillin-resistant strains. In this study, the antimicrobial activities
of nisin, clausin, and amyloliquecidin, separately administered, were compared to that of a mupirocin-based ointment, which is
commonly used as treatment for S. aureus-induced skin infections. Full-thickness excisional wounds, generated on the dorsal
surfaces of mice, were infected with a bioluminescent strain of S. aureus (strain Xen 36). The infections were monitored in real
time using in vivo bioluminescent imaging. Lantibiotic treatments significantly reduced the bioluminescence of S. aureus Xen
36 to a level similar to that recorded with mupirocin treatment. Wound closure, however, was more pronounced during lantibi-
otic treatment. Lantibiotics thus have the potential to be used as an alternative treatment option for S. aureus-induced skin
infections.
Skin and soft tissue infections (SSTIs) are common bacterialinfections, and increased antimicrobial resistance limits the
options available for treatment of SSTIs (1, 2). Mupirocin (Bac-
troban)-based ointments, one of the recommended treatments
for Staphylococcus aureus-induced SSTIs, are losing their effective-
ness, especially against antibiotic-resistant strains, such as methi-
cillin-resistant S. aureus (MRSA) (3, 4). Increased resistance to
vancomycin and linezolid, considered “drugs of last resort” for
severe MRSA and vancomycin-resistant S. aureus infections, re-
spectively, has also been reported (5–8). This further limits treat-
ment options for S. aureus-induced SSTIs, especially those caused
by antibiotic-resistant strains, and alternatives are desperately
needed to ensure future treatment efficacy. As a viable alternative,
researchers have focused on antibiotics that either target cell wall
synthesis or destabilize the cell membrane (9). Certain conserved
cellular components involved in cell wall biosynthesis cannot be
altered or replaced by simple mutations without having a detri-
mental effect on the bacteria, and this makes them valuable targets
(9). Lipid II is an essential precursor in the formation of bacterial
cell walls and is an example of a viable alternative target for next-
generation antibiotics. Lantibiotics are small cationic antimicro-
bial peptides (cAMPs) produced by several Gram-positive bacte-
ria that disrupt cell wall biosynthesis by binding to lipid II (10).
Furthermore, certain lantibiotics, in addition to inhibiting cell
wall biosynthesis, can form pores in the bacterial cell membrane,
resulting in leakage of intracellular material (10). Several lantibi-
otics are active against antibiotic-resistant pathogens, and their
efficacy in treating bacterial infections has been reported in several
animal models (11–14).
Wound healing is as important as treating infection and is a
complex process that involves a number of highly programmed
phases (15, 16). These phases are regulated by the immune system,
which in turn can be negatively influenced by a variety of factors,
including stress, diabetes, obesity, and nutrition (15, 17). Antimi-
crobial peptides, such as cathelicidin LL-37 and defensins, play an
important role in immunity by acting as antimicrobials and/or
immunomodulatory molecules to resolve infection and speed up
the recovery process (18). Lantibiotics are also able to modulate
the innate immune system, with nisin showing promising immu-
nomodulatory activity (19, 20). The immune response triggered
by nisin is able to protect the host against infection caused by
Gram-positive and Gram-negative bacteria. This response is un-
expected, as nisin displays antimicrobial activity toward Gram-
negative bacteria only when combined with a chelating agent or
when the outer membrane has been damaged (20, 21). In an un-
related study, Heunis and coworkers (14) observed accelerated
wound healing when S. aureus-induced skin infections were
treated with nisin incorporated into nanofibers. These studies im-
ply that nisin, and possibly other lantibiotics, may have immuno-
modulatory activity that can be exploited to boost the immune
system to combat infection and enhance wound healing.
Here, we report on the efficacy of the lantibiotics nisin, clausin,
and amyloliquecidin (AmyA), a novel two-component lantibiotic
produced by Bacillus amyloliquefaciens, in treating S. aureus-in-
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duced skin infections. Importantly, the effect on wound healing
and closure was investigated to evaluate the efficacy of these lan-
tibiotics as novel wound repair and regeneration agents.
MATERIALS AND METHODS
Growth media were from Biolab Diagnostics (Gauteng, South Africa)
unless otherwise stated. Polyvinyl alcohol (PVA) (87 to 89% hydrolyzed;
Mw, 146,000 to 186,000) and trifluoroacetic acid (TFA) were from Sigma-
Aldrich (St. Louis, MO). The Pierce bicinchoninic acid (BCA) protein
assay was from Thermo Scientific (Rockford, IL). Gauze and micropore
surgical tape were from AlphaPharm (Stellenbosch, South Africa). Biopsy
punches were supplied by Stellenbosch Medical Supplies (Stellenbosch,
South Africa). Isoflurane was from Safe Saline Pharmaceuticals (Isofor;
Gauteng, South Africa), and buprenorphine was from Schering-Plough
Ltd. (Tamgesic; Cape Town, South Africa).
Preparation of lantibiotics.Lantibiotics were purified and antimicro-
bial activity was tested as discussed in the supplemental material. Freeze-
dried high-performance liquid chromatography (HPLC)-purified sam-
ples were reconstituted in 0.1% (vol/vol) TFA for antimicrobial assays and
phosphate-buffered saline (PBS) (pH 7.4) for animal trials. Peptide con-
centrations were determined using the BCA protein assay according to the
manufacturer’s instructions. Lantibiotics were prepared to a final concen-
tration of 50 M in 0.1% (vol/vol) TFA for antimicrobial assays and 250
M in PBS (pH 7.4) containing 2.5% (wt/vol) PVA for animal trials. The
lantibiotic suspensions were stored at 4°C throughout each animal trial. In
the case of AmyA, the - and -peptides were combined in a 1:1 molar
ratio. The suspensions were freshly prepared before each trial.
Animals used. Ethical clearance to conduct research on animals was
granted by the ethics committee of Stellenbosch University (SU-
ACUM14-00009). Adult female nude mice (weighing 20 to 30 g) were
used for infection studies and housed in separate cages under controlled
environmental conditions (12-h light/dark cycles; 20 to 22°C). The ani-
mals were fed sterile standard rodent feed and water. Closure of nonin-
fected wounds was investigated in male nude mice (weighing 20 to 30 g)
housed under similar conditions. Wound infection studies were con-
ducted in three independent trials, and studies of the closure of nonin-
fected wounds were conducted in two independent trials.
Full-thickness wound generation and infection with S. aureus Xen
36. A full-thickness excisional wound was made on the dorsal surface of
each mouse by using a 6-mm biopsy punch. The mice received buprenor-
phine (0.03 mg/kg of body weight) subcutaneously as an analgesic be-
fore wound generation and for the first 3 days post-wound generation. A
single S. aureus Xen 36 colony was used to inoculate brain heart infusion
(BHI) broth supplemented with kanamycin (200 g/ml) and was incu-
bated overnight at 37°C. The overnight culture was subinoculated into
fresh medium and grown to an optical density at 600 nm (OD600) of 1.0 to
1.2 (2  108 CFU/ml). Cell counts were verified by serial dilution and
plating onto BHI agar supplemented with kanamycin (200 g/ml). Bac-
teria were harvested (10,000  g; 2 min), washed twice with sterile PBS
(pH 7.4), and resuspended in sterile PBS (pH 7.4) to the original OD600.
The wounds were each inoculated with S. aureus Xen 36 (2  106 CFU/
wound), left to dry for 5 min, and then covered with Parafilm and gauze.
The dressings were kept in place with micropore surgical tape.
Treatment and evaluation of S. aureus Xen 36 wound infections.
Mice (n 9 in each treatment group) were left for 3 h postinfection before
treatment commenced. Wounds were treated with 12.5 l (250 M) of
AmyA, clausin, or nisin applied directly onto the wound and dispersed
evenly over the surface. The same volume (12.5 l) of mupirocin oint-
ment (GlaxoSmithKline, Research Triangle Park, NC) was also dispensed
onto wounds using a micrometer syringe attached to a Leur fitting. The
wounds of control mice were treated with 2.5% PVA in PBS (pH 7.4).
The first set of bioluminescent images, recorded using an in vivo im-
aging system (IVIS 100; Caliper Life Sciences, Perkin-Elmer, Hopkinton,
MA), was 5 min after treatment. Follow-up treatments with the same dose
of lantibiotics, mupirocin, and control suspension were 2, 4, and 6 days
after infection. Bioluminescent images were recorded daily for 7 days and
analyzed using Living Image software (v3.0) from Caliper Life Sciences.
Bioluminescence was measured in a region of interest (ROI) (25 by 25
pixels) and expressed as log10 photons per second per square centimeter
per steradian (ps1 cm2 sr1). All images were taken with the dressings
removed. On day 7, the mice were euthanized with an overdose of pent-
abarbitone sodium (Euthapent; Kyron Laboratories Ltd., Benrose, South
Africa). The wounds were excised and homogenized in sterile PBS (pH
7.4), and the homogenate was serially diluted in sterile saline and plated
onto BHI agar supplemented with kanamycin (200 g/ml). The plates
were incubated at 37°C for 24 h, and colonies were enumerated to deter-
mine the numbers of viable S. aureus Xen 36 bacteria present in the
wounds.
Digital images were taken of wounds (n 6 per treatment group) to
determine the effect of treatment on wound closure. Digital photographs
were analyzed using the software program ImageJ (NIH Research Services
Branch [http://rsbweb.nih.gov/ij/]). Wound size on day n was expressed
as a percentage relative to the wound size on day 0 (Dn/D0  100, where
Dn is the wound size on day n and D0 is the wound size on day 0).
Effect of lantibiotics on the closure of noninfected wounds. Full-
thickness excisional wound generation and treatment of mice (n 5 per
treatment group) were as previously described. Digital images of wounds
were taken, and wound closure was determined as previously described.
The mice were monitored for 7 days, after which they were euthanized and
the wounds were excised for histological analysis. The excised wounds
were fixed in 4% formaldehyde in 0.1 M PBS (pH 6.5). Samples were
processed using automated procedures to impregnate and subsequently
embed the samples in paraffin wax. Five-micrometer sections were made
using a rotary microtome, and the samples were stained with hematoxylin
and eosin.
Statistical analysis. All the data were analyzed using GraphPad Prism
(version 6.05), and statistical differences between groups were determined
using two-way analysis of variance (ANOVA) and an unpaired t test. The
statistical analyses used are indicated for each data set. A difference was
considered statistically significant when the P value was 	0.05. Errors
were calculated as standard errors of the mean (SEM).
RESULTS
Lantibiotic activity against S. aureus in vitro. Clinical isolates of
S. aureus, beta-hemolytic streptococci, Enterococcus spp., and Lis-
teria spp. were used as targets to determine the antimicrobial spec-
trum of AmyA, clausin, and nisin (see Tables S1 and S2 in the
supplemental material). All three lantibiotics were active against
S. aureus (including MRSA strains), beta-hemolytic streptococci,
and Listeria spp. Fewer species were inhibited by AmyA, and con-
centrations higher than those of clausin and nisin (based on MIC
values) were required to have the same antibacterial effect against
S. aureus Xen strains (see Table S2 in the supplemental material).
Preliminary MIC values for mupirocin (from mupirocin oint-
ment) against S. aureus Xen 36 (the strain used for in vivo studies)
were less than 5M, and the concentration used on mice was 46.1
mM mupirocin (in 12.5 l mupirocin ointment).
Efficacy of lantibiotics in the treatment of S. aureus-induced
wound infections. Full-thickness excisional wounds on the dorsal
surfaces of mice, generated with a biopsy punch (6-mm diameter),
were infected with 2  106 CFU of the bioluminescent S. aureus
strain Xen 36. The progression of infection was evaluated daily for
7 days by measuring bacterial bioluminescence (IVIS; Perkin-El-
mer, Waltham, MA, USA). Antimicrobial and control treatments
were applied to the wounds 3 h after infection, followed by addi-
tional applications on days 2, 4, and 6 (Fig. 1).
All antimicrobial treatments reduced the bacterial load, as in-
dicated by a reduced bioluminescent signal emitted from S. aureus
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Xen 36 (Fig. 1a and b). Wounds treated with the control polyvinyl
alcohol (CPVA) solution had stable bioluminescence throughout
the 7-day trial period. Treatment with mupirocin (the antibacte-
rial standard for comparison) and nisin resulted in an almost im-
mediate reduction in bioluminescence, i.e., within 5 min of treat-
ment. Significant reductions in bioluminescence readings were
recorded 1 day after treatment with AmyA and clausin. Treatment
with mupirocin resulted in the lowest bioluminescence readings
throughout the trial period (Fig. 1b).
Wounds were excised on day 7, and the number of viable cells
of S. aureus Xen 36 present in the tissue was determined (Fig. 1c).
Viable-cell numbers of S. aureus Xen 36 were significantly and
similarly reduced when wounds were treated with lantibiotics or
mupirocin compared to CPVA treatment. Despite recorded dif-
ferences in bioluminescence, there were no significant differences
in the numbers of S. aureus Xen 36 cells isolated from wound
tissue treated with any of the antimicrobials. Tissue samples with
the highest viable-cell numbers included wounds treated with
CPVA (5.1 107 cells; mean, 1.4 107 cells per wound), followed
by nisin (6.6  105 cells; mean, 1.6  105 cells per wound) and
clausin (7.0 105 cells; mean, 1.6 105 cells per wound).
Effects of antimicrobial treatments on wound closure.
Wound healing can be hampered by infection, and it would thus
be ideal if an antimicrobial agent could also facilitate wound heal-
ing. Wound sizes were therefore measured and compared to those
of CPVA-treated wounds to determine the effects of the lantibiot-
ics on closure in infected wounds (Fig. 2a). All the treatments
resulted in a gradual decrease in wound size, with CPVA, mupi-
rocin, nisin, clausin, and AmyA treatments resulting in 54.8% 

4.6%, 52.7%
 6.9%, 63.9%
 4.7%, 66.7%
 1.6%, and 69.3%

0.7% closure, respectively, after 7 days. All the treatments, includ-
ing CPVA treatment, resulted in smaller wounds on day 7 than
treatment with mupirocin. Clausin- and AmyA-treated wounds
were smaller than CPVA-treated wounds. Although not signifi-
cant, nisin-treated wounds were also smaller than CPVA-treated
wounds.
The effect of antimicrobial treatment on wound closure in the
absence of infection was also studied (Fig. 2b). Noninfected
wounds treated with CPVA, mupirocin, nisin, clausin, and AmyA
resulted in wound closure slightly less than that observed for in-
fected wounds (48.7%
 3.53%, 35.7%
 3.04%, 55.2%
 3.01%,
60.1%
 2.20%, and 55.5%
 4.78%, respectively). However, the
difference was not significant, with the exception of AmyA and
clausin on days 5 and 7 (see Fig. S3 in the supplemental material).
Mupirocin treatment of uninfected wounds resulted in delayed
wound closure; this is in agreement with the closure of infected
wounds treated with mupirocin. Clausin treatment had the most
drastic effect on wound closure, reducing wound size by11.4%
FIG 1 In vivo efficacy of antimicrobials in the treatment of S. aureus-induced skin infection in mice (n 9 per treatment group). (a) Representative images of
in vivo S. aureus bioluminescence following antimicrobial treatment. (b) Dynamics of in vivo S. aureus bioluminescence after antimicrobial treatment. The letters
and brackets above the bars (means and SEM) indicate groups with statistical differences as determined by two-way ANOVA. (c) Viable S. aureus Xen 36 cells
enumerated from excised wounds on day 7. The horizontal lines and brackets represent means and statistical differences, respectively. Statistical analysis was
performed using unpaired t tests.
van Staden et al.
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more than CPVA-treated wounds and24.4% more than mupi-
rocin-treated wounds. Although the difference was not signifi-
cant, AmyA- and nisin-treated wounds were also smaller than
CPVA-treated wounds on day 7.
Histological analysis revealed differences in neutrophil infiltra-
tion, neovascularization, and epithelialization among the differ-
ent groups (Fig. 3). Excised CPVA-treated wounds displayed sig-
nificant epithelialization on day 7, as evidenced by the relatively
thick epithelial layer in the wound area compared to healthy, un-
damaged skin in the same sample. Widespread neovascularization
was visible, with damage to the skin ultrastructure evident at
higher magnification. The significant degree of edema and neu-
trophil infiltration suggests that recovery was in the early inflam-
matory phase. In contrast, in mupirocin-treated wounds, the de-
gree of vascularization was not as pronounced, with the increase in
epithelial layer thickness in the wound area much less than that
observed in CPVA-treated wounds. Mupirocin-treated wounds
showed signs of neovascularization. However, the neovasculariza-
tion response was less pronounced than that observed in CPVA-
treated wounds. The decrease in epithelialization and the delayed
neovascularization associated with mupirocin treatment suggest
that the recovery process may have been delayed, which is sup-
ported by the delayed wound closure. All the lantibiotic-treated
groups were associated with significant epithelialization and neo-
vascularization. Interestingly, these treatments showed less vascu-
larization than CPVA-treated wounds, while the significant epi-
thelialization in these groups argues against a delayed recovery
process. Also, compared to the CPVA-treated group, lantibiotic-
treated groups exhibited relatively few infiltrated neutrophils in
recovering tissue, suggesting that recovery had already progressed
further than in the CPVA-treated controls.
DISCUSSION
The skin is the largest organ in the body and acts as a barrier
protecting the host from the outside environment. The microbi-
ota naturally present on the skin lives in symbiosis with the host
(22). Disruption of the skin barrier can lead to dysbiosis, which in
FIG 2 Effects of antimicrobial treatment on closure of infected and nonin-
fected wounds. The letters and brackets above the bars (means and SEM)
indicate groups with statistical differences as determined by two-way ANOVA.
(a) Closure of wounds infected with S. aureus Xen 36 (n  6 per treatment
group). The gray arrowhead indicates a statistical difference between mupiro-
cin- and AmyA-treated wounds, and the red arrowhead indicates a statistical
difference between CPVA- and clausin-treated wounds, as determined by un-
paired t tests. (b) Closure of noninfected wounds (n 5 per treatment group).
The gray arrowhead indicates a statistical difference between mupirocin- and
CPVA-treated wounds, and the red arrowhead indicates a statistical difference
between CPVA- and clausin-treated wounds, as determined by unpaired t
tests.
FIG 3 Representative photomicrographs of sections from noninfected
wounds excised on day 7, stained with hematoxylin and eosin. The black and
white arrowheads indicate undamaged and damaged tissue, respectively. Scale
bars, 50 m. The images on the left and right were taken at 20 and 40
(within the damaged area) magnification, respectively.
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turn leads to microbial invasion by commensal and noncommen-
sal bacteria. This may result in severe SSTIs and can affect wound
healing (22, 23). This study investigated the efficacy of the lantibi-
otics nisin, clausin, and the newly described AmyA in the treat-
ment of S. aureus-induced skin infections in mice (24). The results
were compared with those obtained using a commercially avail-
able mupirocin-containing ointment. All the lantibiotics used in
the current study were as effective as mupirocin in reducing the
bacterial loads of S. aureus-infected wounds. Importantly, the lan-
tibiotic treatments did not negatively influence wound healing, as
was observed after mupirocin treatment. Wound healing and the
severity of infection can be affected by several factors, including
the route of infection and the immunological response. The route
of infection plays a role in clinical severity, with intradermal and
superficial infections resulting in different inflammatory re-
sponses (4). Athymic nude mice do not display the same clinical
severity of response to intradermal S. aureus infection as wild-type
(BALB/c) mice, with clinical severity proposed to be driven by the
inflammatory response to bacteria rather than the bacterial bur-
den (25). However, in the current study, clinical severity mea-
sured by the rate of wound closure in superficial S. aureus-induced
skin infections in athymic mice was similar to that reported for
superficial S. aureus skin infection studies in wild-type (C57BL/6
or BALB/c) mice (4, 14).
Lantibiotics are classified into distinct classes based on their
modification machinery and further subdivided into different
groups based on amino acid sequence (26, 27). The three lantibi-
otics used in this study are from different classes. Nisin belongs to
the nisin-like lantibiotics and clausin to the epidermin-like lan-
tibiotics. Both are classified as class I lantibiotics. Amyloliquecidin
is a two-component class II lantibiotic, with the individual pep-
tides classified as mersacidin-like (-peptide) and LtnA2-like (-
peptide) lantibiotics (24). Nisin is the prototypical lantibiotic and
is active against several Gram-positive bacterial species, including
antibiotic-resistant strains, and is effective in the treatment of mi-
crobial infections (13, 14, 28–30). Clausin has not been studied to
the same extent, with only a few studies investigating its activity
and mode of action (31, 32). Amyloliquecidin is a newly isolated
lantibiotic, and its antimicrobial activity has not been reported. It
has to be pointed out that, based on amino acid sequence align-
ments, AmyA is different from other two-component lantibiotics,
as well as amylolysin, produced by B. amyloliquefaciens (see Fig. S2
in the supplemental material) (24, 33, 34). Most lantibiotics target
the pyrophosphate moiety of lipid II and subsequently inhibit cell
wall biosynthesis (35, 36). Certain lantibiotics form pores in the
cell membrane after lipid II binding by forming a membrane-
spanning complex (10, 35). Several lantibiotics are active against
antibiotic-resistant pathogens, and their efficacy in treating bac-
terial infections has been reported in several animal models (11–
14, 29, 30). However, resistance to lantibiotics has been described
in the literature, and the majority of the mechanisms responsible
for resistance involve alterations in the charge and permeability of
the cell wall or membrane, respectively (37). Resistance mecha-
nisms include alteration of the cell wall and membrane, such as
increases in the positive charge of the cell wall or changes in the
phospholipid composition of the cell membrane (37–46). Other
resistance mechanisms include biofilms, spore formation, and, in
some cases, specific antilantibiotic mechanisms (37). The devel-
opment of resistance to lantibiotics, specifically alteration of lipid
II, may be reduced due to the unique binding of lantibiotics to the
pyrophosphate moiety, which is essential for lipid II function and
structure (9, 36). Additionally, the dual mode of action of some
lantibiotics poses a significant challenge to target organisms and
may help limit the onset of resistance. These characteristics make
lantibiotics ideal candidates for next-generation antimicrobials.
Little has been published on the in vivo treatment of topical
infections using lantibiotics. However, lantibiotics are effective in
the treatment of S. aureus infections when administered via the
subcutaneous, intraperitoneal, intranasal, and intravenous routes
(11, 12, 29, 30, 47, 48). Nisin incorporated into nanofibers could
be used to treat topical S. aureus infections (14). Nisin-eluting
nanofibers significantly reduced the bacterial load, as shown by
bioluminescence and viable-cell counts, similar to the results of
the current study. These findings are promising, taking into ac-
count the fact that several lantibiotics, including those in the cur-
rent study, are active against antibiotic-resistant strains (11, 12,
28, 47).
The immediate reduction in bioluminescence when wounds
were treated with nisin or mupirocin may be due to their modes of
action (Fig. 2). Nisin inhibits cell wall biosynthesis by binding to
the cell wall precursor lipid II and disrupting peptidoglycan syn-
thesis. Once bound, nisin forms pores in the cell membrane, fol-
lowed by leakage of cellular contents (10, 13, 35). Mupirocin
blocks protein synthesis through inhibition of isoleucyl-tRNA
synthetase and is bactericidal, or bacteriostatic at low concentra-
tions (49–51). The rapid decrease in bioluminescence recorded
when wounds were treated with nisin could be due to rapid cell
lysis, whereas the decrease in readings recorded with mupirocin
treatment could be due to a bactericidal, rather than a bacterio-
lytic, action. Irrespective of the mode of activity, cells of S. aureus
Xen 36 would not be able to emit a detectable bioluminescent
signal. Clausin and AmyA treatment did not show an initial de-
crease in bioluminescence, but there are plausible reasons for this.
Clausin is an epidermin-like lantibiotic, and they are based on
amino acid sequences shorter than those of the nisin-like lantibi-
otics. Although both epidermin-like and nisin-like lantibiotics
can effectively bind to lipid II, pore formation by epidermin-like
lantibiotics is affected by membrane thickness (10). This may ex-
plain the delayed reduction in bioluminescence from cells treated
with clausin. Second, two-component lantibiotics, such as AmyA,
require two peptides to act synergistically to induce cellular leak-
age. The -peptide binds to lipid II, followed by binding of the
-peptide to the-peptide–lipid II complex. This interaction then
results in pore formation (52). Thus, in an in vivo situation, it can
be expected that the reaction may take place at a reduced rate
and could therefore account for AmyA not being able to rapidly
reduce bioluminescence. It is also possible that one or both of
the AmyA peptides interact with lipids/membranes other than
those found in the target organism and, by doing so, delay
antimicrobial activity.
From this study, it is evident that lantibiotics, in addition to
controlling infection, do not negatively influence wound healing
compared to CPVA and mupirocin treatments, with similar ef-
fects observed for wound closure in both infected and noninfected
wounds. In contrast, despite the effectiveness of mupirocin in re-
ducing the bacterial burden, it delayed wound closure compared
to all the other treatments. The observation in the mupirocin-
treated wounds of less epithelialization, as well as the delayed neo-
vascularization, suggests that the recovery process may have been
delayed (53). Similar cases of delayed wound closure have been
van Staden et al.
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reported for mupirocin formulations (54). These facts add to the
concern raised by an actual delayed wound closure rate associated
with mupirocin, which highlights the necessity to find more suit-
able alternatives, such as the ones reported in the current study.
The composition of the drug delivery vehicle can also influence
antimicrobial effectiveness and wound healing (4, 55). Interest-
ingly, there were no significant differences in wound closure be-
tween infected and noninfected wounds treated with CPVA. Kim
and coworkers (56) reported similar results while studying the
dynamics of neutrophil infiltration during full-thickness wound
healing in mice. In their study, mice were intraperitoneally in-
jected with granulocyte-macrophage colony-stimulating factor
(GM-CSF) (wounds not infected) or saline (wounds not infected)
or, alternatively, not injected (wounds infected with S. aureus).
The authors found that, despite an increase in neutrophil recruit-
ment resulting from infection with S. aureus or treatment with
GM-CSF, wound closure rates in all groups were similar to that of
the saline-injected control. In our study, the lantibiotics did not
negatively influence wound closure, with all wounds being smaller
than CPVA- and mupirocin-treated wounds (Fig. 2). These re-
sults, along with those from the histological analysis, may indicate
an alternative or additional mechanism by which lantibiotics fa-
cilitate regeneration of damaged tissue. Similar results were ob-
tained when wounds were treated with nisin-eluting nanofibers,
including earlier signs of epithelialization and lack of neutrophil
infiltration (14), suggesting faster resolution of inflammation and
more efficient tissue repair. Lantibiotics are able to induce chemo-
kines involved in wound healing. Interleukin 8, growth-related
oncogene, and monocyte chemoattractant protein 1 are induced
by nisin and gallidermin, with nisin treatment resulting in stron-
ger induction of these chemokines (20). Nisin and gallidermin are
classified into different groups, namely, nisin-like and epidermin-
like lantibiotics, respectively. The lantibiotics in the current study
were also from different groups, and although not statistically sig-
nificant, differences in the effects of these lantibiotics were evi-
dent. This indicates that structural differences in lantibiotics pos-
sibly influence their modulation of the immune system.
In conclusion, we have demonstrated the effectiveness of lan-
tibiotics in the treatment of S. aureus-induced skin infections, as
well as their effects on the closure of infected and noninfected
wounds. Of particular interest is the fact that the current study is
the first to investigate and report on the antimicrobial properties
of the newly identified two-component lantibiotic amyloliqueci-
din. From the data reported here, it is evident that the lantibiotics
assessed are as effective in reducing the bacterial load on wounds
as mupirocin treatment, which is one of the recommended treat-
ments for S. aureus-induced skin infections. Furthermore, treat-
ment with lantibiotics is equivalent to or better than treatment
with mupirocin, especially with respect to wound closure rates.
The specific role(s) of these promising lantibiotics in wound heal-
ing and how their structural properties might influence this inter-
action are areas that require further investigation. However, the
efficacy in terms of both antimicrobial and wound-healing prop-
erties of the lantibiotics used in this study, compared to mupiro-
cin, effectively illustrates the potential of lantibiotics in the treat-
ment of skin infections.
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